GB201513740D0 - Muscarinic agonist - Google Patents

Muscarinic agonist

Info

Publication number
GB201513740D0
GB201513740D0 GBGB1513740.9A GB201513740A GB201513740D0 GB 201513740 D0 GB201513740 D0 GB 201513740D0 GB 201513740 A GB201513740 A GB 201513740A GB 201513740 D0 GB201513740 D0 GB 201513740D0
Authority
GB
United Kingdom
Prior art keywords
muscarinic agonist
muscarinic
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1513740.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GBGB1513740.9A priority Critical patent/GB201513740D0/en
Publication of GB201513740D0 publication Critical patent/GB201513740D0/en
Priority to AU2016302047A priority patent/AU2016302047B2/en
Priority to CN201680045225.6A priority patent/CN107949384B/zh
Priority to ES16750221T priority patent/ES2894855T3/es
Priority to HK18109573.6A priority patent/HK1250139B/en
Priority to JP2018504993A priority patent/JP6847093B2/ja
Priority to PCT/GB2016/052384 priority patent/WO2017021728A1/en
Priority to US15/749,743 priority patent/US10548884B2/en
Priority to DK16750221.0T priority patent/DK3331528T3/da
Priority to EP16750221.0A priority patent/EP3331528B1/en
Priority to CA2994143A priority patent/CA2994143C/en
Priority to US16/728,762 priority patent/US11324738B2/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1513740.9A 2015-08-03 2015-08-03 Muscarinic agonist Ceased GB201513740D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB1513740.9A GB201513740D0 (en) 2015-08-03 2015-08-03 Muscarinic agonist
CA2994143A CA2994143C (en) 2015-08-03 2016-08-03 Muscarinic agonists
HK18109573.6A HK1250139B (en) 2015-08-03 2016-08-03 Muscarinic agonists
CN201680045225.6A CN107949384B (zh) 2015-08-03 2016-08-03 毒蕈碱激动剂
ES16750221T ES2894855T3 (es) 2015-08-03 2016-08-03 Agonistas muscarínicos
AU2016302047A AU2016302047B2 (en) 2015-08-03 2016-08-03 Muscarinic agonists
JP2018504993A JP6847093B2 (ja) 2015-08-03 2016-08-03 ムスカリン様アゴニスト
PCT/GB2016/052384 WO2017021728A1 (en) 2015-08-03 2016-08-03 Muscarinic agonists
US15/749,743 US10548884B2 (en) 2015-08-03 2016-08-03 Muscarinic agonists
DK16750221.0T DK3331528T3 (da) 2015-08-03 2016-08-03 Muskarinagonister
EP16750221.0A EP3331528B1 (en) 2015-08-03 2016-08-03 Muscarinic agonists
US16/728,762 US11324738B2 (en) 2015-08-03 2019-12-27 Muscarinic agonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1513740.9A GB201513740D0 (en) 2015-08-03 2015-08-03 Muscarinic agonist

Publications (1)

Publication Number Publication Date
GB201513740D0 true GB201513740D0 (en) 2015-09-16

Family

ID=54063147

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1513740.9A Ceased GB201513740D0 (en) 2015-08-03 2015-08-03 Muscarinic agonist

Country Status (10)

Country Link
US (2) US10548884B2 (enExample)
EP (1) EP3331528B1 (enExample)
JP (1) JP6847093B2 (enExample)
CN (1) CN107949384B (enExample)
AU (1) AU2016302047B2 (enExample)
CA (1) CA2994143C (enExample)
DK (1) DK3331528T3 (enExample)
ES (1) ES2894855T3 (enExample)
GB (1) GB201513740D0 (enExample)
WO (1) WO2017021728A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014012056B1 (pt) 2011-11-18 2021-12-14 Heptares Therapeutics Limited Compostos agonistas do receptor m1 muscarínico, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou psicótico ou para tratamento ou diminuição da severidade da dor aguda, crônica, neuropática ou inflamatória
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201726675A (zh) 2015-12-23 2017-08-01 默沙東藥廠 M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
HUE061533T2 (hu) * 2018-03-23 2023-07-28 Pfizer Piperazin azaspiro származékok
GB201810239D0 (en) * 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
TWI849432B (zh) * 2019-09-25 2024-07-21 波蘭商摩爾治療股份公司 製造5-(4-((2s,5s)-5-(4-氯芐基)-2-甲基嗎啉基)哌啶-1-基)-1h-1,2,4-三唑-3-胺的方法
PH12022550860A1 (en) * 2019-10-09 2023-06-14 Novartis Ag 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists
JOP20220082A1 (ar) 2019-10-09 2023-01-30 Novartis Ag مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
EP4069367B1 (en) 2019-12-06 2024-05-15 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
JP7707176B2 (ja) * 2020-02-05 2025-07-14 ニューロクライン バイオサイエンシーズ,インコーポレイテッド ムスカリン性受容体4アンタゴニストおよび使用方法
EP4447953A1 (en) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2025030095A1 (en) * 2023-08-03 2025-02-06 Neurocrine Biosciences, Inc. Methods of synthesis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080094964A (ko) 2006-02-22 2008-10-27 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제
ATE517106T1 (de) * 2006-02-22 2011-08-15 Vertex Pharma Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
WO2010049146A1 (en) 2008-10-29 2010-05-06 Grünenthal GmbH Substituted spiroamines
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
BR112014012056B1 (pt) * 2011-11-18 2021-12-14 Heptares Therapeutics Limited Compostos agonistas do receptor m1 muscarínico, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou psicótico ou para tratamento ou diminuição da severidade da dor aguda, crônica, neuropática ou inflamatória
CA2883210C (en) * 2012-09-18 2021-06-15 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists
JP6478923B2 (ja) * 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited ムスカリンm4受容体アゴニストとしてのピペリジン−1−イル及びアゼピン−1−イルカルボキシレート
MX393637B (es) * 2014-02-06 2025-03-11 Heptares Therapeutics Ltd Compuestos aza biciclicos como agonistas del receptor muscarinico m1.
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists

Also Published As

Publication number Publication date
ES2894855T3 (es) 2022-02-16
WO2017021728A1 (en) 2017-02-09
CA2994143C (en) 2023-09-26
CN107949384A (zh) 2018-04-20
JP2018522034A (ja) 2018-08-09
JP6847093B2 (ja) 2021-03-24
AU2016302047A1 (en) 2018-02-15
DK3331528T3 (da) 2021-10-25
US20200129496A1 (en) 2020-04-30
US10548884B2 (en) 2020-02-04
EP3331528A1 (en) 2018-06-13
CA2994143A1 (en) 2017-02-09
HK1250139A1 (en) 2018-11-30
AU2016302047A8 (en) 2018-03-08
US20180228791A1 (en) 2018-08-16
US11324738B2 (en) 2022-05-10
WO2017021728A9 (en) 2017-04-27
AU2016302047B2 (en) 2020-09-10
CN107949384B (zh) 2025-02-28
EP3331528B1 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
ZA201800715B (en) Muscarinic agonists
GB201513740D0 (en) Muscarinic agonist
GB201501297D0 (en) Device
GB201513743D0 (en) Muscarinic agonists
SG11201607458QA (en) Muscarinic receptor agonists
GB2537033B (en) Device
PL3328248T3 (pl) Ulepszone przesuwne pionowo urządzenie do zawieszania ubrań
SG11201708455YA (en) Shutoff-opening device
GB201521136D0 (en) Device
GB201515777D0 (en) Device
TWI562713B (en) Elcetronic device
HUE056371T2 (hu) Átömlesztõ eszköz
EP3265466A4 (en) Peripheral-anticholinergic muscarinic agonist combination
GB201519583D0 (en) Device
ZA201704941B (en) Pondage device
HUE043830T2 (hu) Visszalökés-csillapító szerkezet
GB201610183D0 (en) Structure
PL3391016T3 (pl) Urządzenie próbkujące
IL237991A0 (en) Player
ZA201807587B (en) Polytunnel structure
GB201610190D0 (en) Structure
PT3075370T (pt) Dispositivo de automassagem
GB201520882D0 (en) Device
GB201520322D0 (en) Device
GB201513473D0 (en) Device

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)